Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy

Neurologists are interested in understanding whether patients with multiple sclerosis (pwMS) undergoing immunomodulatory/immunosuppressive therapy are more susceptible to developing COVID-19 or have worse outcomes. Currently, there are no conclusive data in this regard. We report the prevalence and...

Descripción completa

Detalles Bibliográficos
Autores principales: Crescenzo, Francesco, Marastoni, Damiano, Bovo, Chiara, Calabrese, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335234/
https://www.ncbi.nlm.nih.gov/pubmed/32650121
http://dx.doi.org/10.1016/j.msard.2020.102372
Descripción
Sumario:Neurologists are interested in understanding whether patients with multiple sclerosis (pwMS) undergoing immunomodulatory/immunosuppressive therapy are more susceptible to developing COVID-19 or have worse outcomes. Currently, there are no conclusive data in this regard. We report the prevalence and severity of COVID-19 (confirmed and possible) in pwMS followed at the Veneto Regional MS Center in Verona (Italy), an area most stricken by COVID-19. In our sample size, the prevalence of COVID-19 seems to be much higher than that officially reported at the regional level on the general population, but it also characterized by a favourable course.

Ejemplares similares